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Co-transcriptional degradation of aberrant
pre-mRNA by Xrn2
Lee Davidson, Alastair Kerr and
Steven West*
Wellcome Trust Centre for Cell Biology, University of Edinburgh,
Edinburgh, UK
Eukaryotic protein-coding genes are transcribed as
pre-mRNAs that are matured by capping, splicing and
cleavage and polyadenylation. Although human pre-
mRNAs can be long and complex, containing multiple
introns and many alternative processing sites, they are
usually processed co-transcriptionally. Mistakes during
nuclear mRNA maturation could lead to potentially harm-
ful transcripts that are important to eliminate. However,
the processes of human pre-mRNA degradation are not
well characterised in the human nucleus. We have studied
how aberrantly processed pre-mRNAs are degraded and
find a role for the 50-30 exonuclease, Xrn2. Xrn2 associ-
ates with and co-transcriptionally degrades nascent
b-globin transcripts, mutated to inhibit splicing or 30 end
processing. Importantly, we provide evidence that many
endogenous pre-mRNAs are also co-transcriptionally
degraded by Xrn2 when their processing is inhibited
by Spliceostatin A. Our data therefore establish a pre-
viously unknown function for Xrn2 and an important
further aspect of pre-mRNA metabolism that occurs
co-transcriptionally.
The EMBO Journal (2012) 31, 2566–2578. doi:10.1038/
emboj.2012.101; Published online 20 April 2012
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Introduction
Eukaryotic pre-mRNA transcripts are synthesised by RNA
polymerase II (Pol II). They are matured by capping, splicing
and 30 end cleavage and polyadenylation before the mRNA is
exported into the cytoplasm and translated (Moore and
Proudfoot, 2009). In vivo, most processing is thought to
occur co-transcriptionally via the recruitment of pre-mRNA
processing factors to the c-terminal domain (CTD) of the
large subunit of RNA polymerase II (Pol II) (Buratowski,
2009). This is at least in part governed by phosphorylation
of serines 2, 5 and 7 within the CTD heptapeptide repeat
sequence, YSPTSPS (Bentley, 2005; Corden, 2007; Kim et al,
2010; Schwer and Shuman, 2011). Most human pre-mRNAs
contain multiple exons separated by much larger intron
sequences and more than 90% may be alternatively spliced
or 30 end processed to produce multiple mRNA isoforms
(Wang et al, 2008; Ozsolak et al, 2010).
Although productive processing is frequently transcription
coupled, other potentially co-transcriptional aspects of mRNA
metabolism and biogenesis have not been explored in detail.
Recent studies indicated that transcripts deriving from mutant
gene templates are retained at or close to their site of synth-
esis implying that degradation was occurring there (Custodio
et al, 1999; de Almeida et al, 2010; Martins et al, 2011).
However, other blocks to splicing cause some transcripts to
accumulate in the nucleoplasm or even, in the case of some
budding yeast transcripts, in the cytoplasm (Hilleren and
Parker, 2003; Kaida et al, 2007; Brody et al, 2011; Martins
et al, 2011). Although temporal and spatial aspects of decay
are not well understood, many exonucleolytic enzymes that
execute degradation are well defined.
The exosome plays a major role in pre-mRNA turnover in
eukaryotes. It is a multi-protein complex where 30-50
exonuclease activity is provided by its Rrp44/Dis3 subunit
and Rrp6 co-factor (Dziembowski et al, 2007; Schmid and
Jensen, 2008). Interestingly, Rrp44/Dis3 also possesses
endonuclease activity (Lebreton et al, 2008; Schneider et al,
2009). Loss of S. cerevisiae exosome function stabilises
transcripts that are splicing or 30 end processing defective
(Bousquet-Antonelli et al, 2000; Torchet et al, 2002). The
budding yeast exosome is also required for the retention of
some aberrant mRNAs at their site of synthesis (Hilleren et al,
2001). Similarly, depletion of the human homologue of Rrp6
(hRrp6) causes b-globin transcripts carrying deletions or
mutations in intron 2 to be released from their site of
synthesis (de Almeida et al, 2010; Eberle et al, 2010). In
Drosophila the exosome has been found associated with the
Pol II elongation factor Spt5 and with nascent mRNPs
highlighting the possibility that surveillance is
co-transcriptional (Andrulis et al, 2002; Hessle et al, 2009).
Human and S. cerevisiae nuclei also contain 50-30 exo-
nucleases: Xrn2 and Rat1 respectively. Xrn2 and Rat1 degrade
the Pol II associated product of poly(A) site cleavage, which is
important for Pol II termination (Kim et al, 2004; Gromak
et al, 2006). In the case of the human b-globin gene,
co-transcriptional cleavage of terminator transcripts
generates entry sites for Xrn2 (West et al, 2004). Xrn2 is
also involved in processing and degradation of many
ribosomal RNAs (Wang and Pestov, 2010). Other functions
of Rat1 include degradation of some splice defective
pre-mRNAs (Bousquet-Antonelli et al, 2000), transcripts
that fail to acquire a cap (Jimeno-Gonzalez et al, 2010),
RNA transcribed from telomeric repeats (Luke et al, 2008)
and promoting transcriptional termination of Pol I (El Hage
et al, 2008; Kawauchi et al, 2008).
We have examined mechanisms used for degrading aber-
rant transcripts as well as their timing with relation to
transcription. Analysis of nascent transcripts provides strong
evidence that degradation of b-globin pre-mRNA blocked in
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splicing or 30 end processing is co-transcriptional. Similar to
previous reports we find a role for the exosome in degrading
some aberrant b-globin transcripts but also find that the
50-30 exonuclease Xrn2 binds to aberrant b-globin tran-
scripts that are stabilised by its depletion. Some nascent
endogenous pre-mRNA transcripts are also stabilised by
Xrn2 depletion following use of the splicing inhibitor,
Spliceostatin A. These data indicate that co-transcriptional
degradation of RNA is an important means of exerting quality
control on transcription.
Results
To begin to study the degradation of aberrant pre-mRNA, we
used five plasmids containing different versions of the human
b-globin gene each driven by the HIV promoter (Figure 1A).
These were an unmodified wild type (WT) gene, one with a
mutated 30 splice site in intron 1 (In1m), one with a mutant
poly(A) site (pAm), as well as versions of In1m and pAm
lacking the 30 flanking sequence necessary for termination
(DTIn1m and DTpAm). These constructs enabled us to assay
the implications of splicing and 30end processing failure and
any additional effect of the terminator sequence, which is
known to be important for efficient mRNA production (West
and Proudfoot, 2009).
We first assayed for b-globin RNA levels from each con-
struct. HeLa cells were transfected with each b-globin
plasmid and a construct containing the Pol III transcribed
VA gene, which acts as a control for equivalent transfection
efficiency. Total RNA was then isolated and reverse tran-
scribed using random hexamers. To detect all processed and
unprocessed forms of b-globin RNA, cDNA was real time PCR
amplified using primers directed to exon 3 (Figure 1B).
Following correction to VA transcript levels, we observed
fewer b-globin transcripts in samples from cells transfected
with mutant constructs when compared to the WT suggesting
that the mutations somehow inhibit b-globin RNA produc-
tion. One way that this could be achieved is through reduced
transcription. However, transcription of these plasmids has
been analysed previously where it was found to be reduced
only up to 2-fold (Dye and Proudfoot, 1999; Dye and
Proudfoot, 2001). Since the reduction in RNA that we
observe is much greater than that, particularly for DTIn1m,
pAm and DTpAm, we hypothesised that many mutant
transcripts were being degraded, possibly as a result of
impaired processing.
To understand more about the effects of the mutations on
pre-mRNA processing, we next assayed total RNA from the
same samples using Northern blotting with a probe directed
to exon 3 (Figure 1C). To control for transfection variance we
analysed RNA from a co-transfected plasmid expressing
erythropoietin (EPO). We observed a strong band corre-
sponding to b-globin mRNA in the WT sample. In contrast,
much weaker bands were observed in In1m and DTIn1m
samples, which were larger owing to intron 1 inclusion
caused by the mutated splice site. No obvious product was
detected in pAm and DTpAm samples. These data confirm
that the intron 1 and pA mutations prevent the accumulation
of any correctly processed b-globin mRNA. Additional real-
time PCR data confirmed the inhibitory effects of the muta-
tions on splicing and 30 end processing (Supplementary
Figure 1).
The data so far show that the mutations employed here
prevent b-globin mRNA accumulation and reduce the overall
level of b-globin RNA detectable in the total RNA fraction. For
a more detailed insight into RNA production from mutant
templates, we analysed transcripts from each b-globin gene in
three different cellular fractions. We used a well characterised
technique to isolate chromatin-associated, nucleoplasmic and
cytoplasmic RNA from HeLa cells transfected with each
b-globin plasmid and the EPO control plasmid (Wuarin and
Schibler, 1994). To detect the full range of transcripts, each
sample was analysed by Northern Blotting using the b-globin
exon 3 probe (Figure 1D). In the chromatin fraction, we
observed a band representing spliced b-globin in WT samples
but no predominant species in any other sample. A lack of
product indicates that mutant RNA is either not produced, is
very unstable or does not accumulate sufficient amounts of
any distinct species to be detected by Northern analysis.
A strong band corresponding to mature b-globin mRNA was
observed in nucleoplasmic and cytoplasmic WT samples.
Much fainter bands were seen in nucleoplasmic and
cytoplasmic In1m and DTIn1m samples corresponding to
RNA retaining intron 1. Very little pAm or DTpAm product
was detected. The observation that only spliced and 30 end
processed RNA predominates in nucleoplasmic and cytoplas-
mic fractions is consistent with the idea that pre-mRNA
processing occurs before transcripts are released from chro-
matin (Dye et al, 2006).
We wished to resolve whether mutant transcripts were
absent from any fraction or whether they were undetectable
by Northern analysis due to their heterogeneous nature. We
therefore performed real-time RT-PCR on chromatin and
nucleoplasmic RNA isolated from HeLa cells transfected
with each b-globin plasmid as well as the VA control plasmid.
cDNA was synthesised using random hexamers together with
a primer specific to b-globin exon 3 and exon 3 containing
RNA was quantitated by real-time PCR (Figure 1E). This
assay permits detection of the total population of RNA
containing exon 3 even if it is heterogeneous in nature.
Differences in transfection and fractionation efficiencies
were corrected for by analysing VA and GAPDH RNA
levels (see Materials and methods). Interestingly, there
were similar levels of exon 3 RNA in all chromatin samples.
These data imply that product deriving from mutant
chromatin RNA cannot be detected by Northern Analysis
due to its heterogeneous nature. Consistent with the
Northern analysis, we detected high levels of exon 3 contain-
ing WT RNA in the nucleoplasm, indicating efficient release
of these RNAs. In contrast, only half as much In1m RNA was
recovered from the nucleoplasm compared to chromatin and
even less was detected in pAm, DTIn1m and DTpAm nucleo-
plasmic samples. Thus, mutant nucleoplasmic RNA is
detected at much lower amounts than WT RNA by both
Northern and qRT-PCR analysis. We conclude that mutated
b-globin RNA is predominantly chromatin-based, which is
consistent with previous reports utilising microscopy-based
approaches (Custodio et al, 1999). The release of more In1m
transcripts compared to the other mutant RNAs might be
explained by observations that Pol II termination is occurring
on this construct (Supplementary Figure 1 and (Dye and
Proudfoot, 1999)). In line with this, Pol II termination is
important for the release of RNA from chromatin (West et al,
2008).
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We next analysed spliced (exon 2-exon 3) RNA from the
same samples (Figure 1F). As with exon 3 RNA, spliced WT
transcript were efficiently released into the nucleoplasm.
There were much fewer spliced transcripts in the chromatin
fraction for all mutant transcripts compared to WT, which is
consistent with the above Northern analysis and reflects the
expected impairment of splicing caused by the mutations.
Similarly, very little spliced mutant transcripts were observed
in the nucleoplasm. We also analysed the location of exon
1-exon 2 products in WT, pAm and DTpAm (Supplementary
Figure 2). Although similar levels of this product were
observed between the WT and mutant transcripts in the
chromatin fraction only WT RNA was released into the
nucleoplasm. Thus, a single successful splicing event is
insufficient for release. In summary, although similar levels
of chromatin RNA are recovered from WT and mutant gene
templates, WT transcripts are much more efficiently pro-
cessed and released as judged by their recovery in the
A
1 2
pA
X
WT
-Globin
3
W
T
In
1m
ΔT
In
1m
pA
m
ΔT
pA
m
W
T
In
1m
ΔT
In
1m
pA
m
ΔT
pA
m
W
T
In
1m
ΔT
In
1m
pA
m
ΔT
pA
m
D 1 2
pA
3
E3
pAm
In1m
ΔTIn1m
ΔTpAm
1 2
pA
1 2
pA
1 2
pA
1 2
X X
3
3
3
3
1 2 3
1 2 3
pAX
EPO
Chromatin Nucleoplasm Cytoplasm
0.6
0.8
1
B
*
WT
In1m
pAm
ΔTIn1m2
2.5
**
E
1 2
pA
3
1 2
pA
3
0
0.2
0.4
R
el
at
iv
e 
ex
on
 3
 R
NA
le
ve
l
ΔT
In1
m 
ΔT
pA
mWT In1
m
pA
m
** **
**
ΔTpAm
0.5
1
1.5
*
** **
C
R
el
at
iv
e 
ex
on
 3
 R
NA
 le
ve
l
0
Chromatin Nucleoplasm
F1 2 3
E3
4.5
2 3
WT In1
m pA
m
ΔT
In1
m 
ΔT
pA
m
1 2 3
1 2 3
pA
2
2.5
1.5
3
3.5
4 WT
In1m
pAm
ΔTIn1m
ΔTpAm
EPO
0
0.5
1
R
el
at
iv
e 
E2
E3
 R
NA
 le
ve
l
Chromatin
**
Nucleoplasm
Figure 1 Aberrant b-globin transcripts are degraded at chromatin sites. (A) Schematic diagram of the plasmids used to study b-globin pre-
mRNA degradation. The HIV promoter (arrow) is followed by the b-globin gene with numbered exons (black boxes), pA signal (pA), and
terminator element (grey box) indicated. The In1m, pAm, DTIn1m and DTpAm derivatives are also shown and the position of respective
mutations is indicated with a cross. (B) Real-time PCR analysis of exon 3-containing b-globin transcripts in total RNA isolated from WT, In1m,
pAm, DTIn1m and DTpAm transfected cells. Diagram shows the position of the primer pair (arrows). Quantitation is expressed in relation to
values obtained from WT samples, which were set to 1 following normalisation to signal from co-transfected VA. (C) Northern blotting of total
RNA isolated from WT, In1m, pAm, DTIn1m and DTpAm transfected cells. Spliced and partially spliced products as well as the EPO co-
transfection product are indicated. Diagram shows exon 3 probe (grey line). (D) Northern blotting of chromatin-associated, nucleoplasmic and
cytoplasmic RNA isolated from WT, In1m, pAm, DTIn1m and DTpAm transfected cells. Spliced and partially spliced products as well as the
EPO co-transfection product are indicated. Diagram shows exon 3 probe (grey line). (E) Real-time PCR analysis of exon 3 b-globin transcript
levels in chromatin-associated and nucleoplasmic RNA isolated from cells transfected with WT, In1m, pAm, DTIn1m or DTpAm. Diagram
shows the positions of primer pairs used. Quantitation is in relation to values obtained from WT samples, which were set to 1 following
normalisation to signal from co-transfected VA. (F) Real-time PCR analysis of exon 2-exon 3 b-globin transcript levels in chromatin-associated
and nucleoplasmic RNA isolated from cells transfected with WT, In1m, pAm, DTIn1m or DTpAm. Diagram shows the positions of primer pairs
used. Quantitation is in relation to values obtained from WTsamples, which were set to 1 following normalisation to signal from co-transfected
VA. All error bars represent the standard deviation from the mean (s.d.) from a minimum of three biological replicates. * and **indicate P-
values of o0.05 and o0.01 respectively. Figure source data can be found with the Supplementary data.
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nucleoplasmic and cytoplasmic fractions. The presence of
lower overall levels of mutant RNAs implies that they are
degraded, which is likely to be a result of impaired proces-
sing. Since we only recover large amounts of mutant RNA
from the chromatin fraction, we hypothesised that degrada-
tion was most likely to occur at the chromatin or otherwise
very soon after release into the nucleoplasm.
The role of exonucleases in degrading aberrant b-globin
transcripts
We sought to identify the enzymes responsible for nuclear
degradation of the mutant b-globin transcripts and to deter-
mine whether degradation was associated with the chromatin
or nucleoplasmic fractions. We initially analysed the human
homologue of S. cerevisiae Rrp6 (hRrp6), since previous
reports indicated an important function for it in human pre-
mRNA surveillance (de Almeida et al, 2010; Eberle et al,
2010). We used RNAi to deplete hRrp6 from HeLa cells
(Figure 2A). Chromatin-associated and nucleoplasmic RNA
was isolated from mock treated and hRrp6 depleted cells
transfected with each b-globin construct and the VA plasmid.
Following reverse transcription, cDNA was amplified with
primers directed to exon 3 (Figure 2B). After normalising to
VA, similar levels of WT RNA were observed in mock treated
and hRrp6 depleted cells indicating that these transcripts are
not substrates for this protein. There were modest increases
in mutant transcripts levels in the chromatin and nucleoplas-
mic fractions upon hRrp6 depletion, which we also observed
upon depleting the Rrp44/Dis3 subunit of the exosome
(Supplementary Figure 3). Although these effects are small,
they are consistent with previous reports of hRrp6 function in
the surveillance of aberrant b-globin RNAs (de Almeida et al,
2010; Eberle et al, 2010).
The small effects observed following depletion of catalytic
exosome components may reflect the activity of residual
protein remaining following siRNA treatment or the compen-
satory action of the other catalytic subunit. There may also be
other transcript degradation pathways operating on the RNAs
studied here. Indeed, many budding yeast pre-mRNAs are
sensitive to depletion of either the exosome or the 50-30
exonuclease, Rat1 (Bousquet-Antonelli et al, 2000; Egecioglu
et al, 2011). To study any role for the human homologue of
Rat1, Xrn2, we depleted it from HeLa cells using RNAi
(Figure 2C). Chromatin-associated and nucleoplasmic RNA
was then isolated from mock treated and Xrn2 depleted cells
transfected with the b-globin plasmids and the VA plasmid.
Following reverse transcription with an exon 3 specific pri-
mer, cDNA was analysed by real-time PCR using exon 3
primers (Figure 2D). Depletion of Xrn2 did not alter the
level of WT transcripts in either nuclear fraction after normal-
ising to VA. In1m transcripts were also unaffected indicating
that they are also not substrates for Xrn2. However, pAm,
DTIn1m and DTpAm transcripts were stabilised in both
fractions upon Xrn2 depletion. It is interesting that Xrn2
does not target In1m transcripts but degrades DTIn1m
RNAs. This differential effect might be explained by the
efficient termination on In1m (Supplementary Figure 1 and
(Dye and Proudfoot, 1999)), which might facilitate the escape
of transcripts from chromatin associated Xrn2. Importantly,
Xrn2 depletion stabilised chromatin and nucleoplasmic
transcripts to an equal degree (B2–3-fold). Because most of
these mutant RNAs are chromatin-associated (Figure 1E), this
strongly suggests that the majority of Xrn2 sensitive tran-
scripts are also chromatin-associated. If degradation was
nucleoplasmic, we would instead expect a larger effect in
this fraction with minimal stabilisation of chromatin RNA.
We also analysed the effect of Xrn2 depletion on the level
of spliced b-globin transcripts (exon2-exon3) from each
gene version in chromatin and nucleoplasmic fractions
(Figure 2E). There was no effect of Xrn2 depletion on spliced
WT or In1m transcripts. However, Xrn2 depletion increased
the level of spliced transcripts for all other mutant b-globin
versions and in each cell fraction. This suggests that spliced
mutant transcripts are also substrates for Xrn2 or that
reduced degradation allows a suboptimal splicing process to
succeed.
Degradation by Xrn2 is co-transcriptional
We wished to explore the potential function for Xrn2 in
degrading aberrant transcripts further given that its role in
human nuclear RNA turnover is less well characterised than
that of the exosome. In particular, the stabilisation of
chromatin-associated RNA upon its depletion indicates a
co-transcriptional degradation process given previous find-
ings that this fraction is enriched in nascent RNA (Wuarin
and Schibler, 1994). To test this hypothesis, we developed an
alternative means to isolate a purer nascent RNA fraction. We
performed a nuclear run on (NRO) assay to label nascent
RNA with 4-thioUTP (Figure 3A). During NRO, Pol II elon-
gates 100–200 nucleotides thereby labelling the very 30 end of
nascent RNA (Dye and Proudfoot, 2001; Core et al, 2008).
4-thio UTP labelled nascent RNA is then biotinylated and
specifically enriched from non-labelled RNA following
capture by streptavidin coated beads. NRO RNA is normally
fragmented to resolve positions of actively transcribing Pol II
but we left the transcripts intact to better determine their
splicing status and stability.
It was important to initially test whether the assay was
capable of detecting Xrn2-dependent changes in nascent RNA
levels. We showed that this was the case by detecting the
increased levels of read-through b-globin transcripts pre-
viously shown, by NRO, to accumulate following Xrn2 deple-
tion (Supplementary Figure 4) and (West et al, 2004). Next,
we performed this procedure on nuclei isolated from mock or
Xrn2 depleted HeLa cells transfected with WT, DTIn1m or
DTpAm, together with VA (Figure 3B). Isolated nascent
transcripts were reverse transcribed and subjected to real-
time PCR analysis to quantitate both exon 3 containing and
spliced (exon 2-exon 3) RNA. After normalising to VA, no
change in the level of WT transcripts was observed between
the control and Xrn2 depleted cells consistent with the
Figures 2D and E. However, B2-fold more nascent exon 3
containing and spliced RNA was observed in Xrn2 depleted
cells transfected with DTIn1m or DTpAm. These data provide
additional evidence that many DTIn1m and DTpAm tran-
scripts are co-transcriptionally degraded by Xrn2.
Pol II loading is unchanged by Xrn2 depletion
An alternative explanation for increased levels of aberrant
pre-mRNA in Xrn2 depleted cells would be increased Pol II
density on mutant gene templates leading to greater RNA
production. We tested for this by analysing Pol II loading by
chromatin immunoprecipiation (ChIP). Antibodies to total/
serine 5 phosphorylated CTD (4H8) or to serine 2 phosphory-
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lated CTD (S2) were used to immunoprecipitate DNA from
control or Xrn2 depleted cells transfected with DTIn1m and
DTpAm (Figure 3C). Although ChIP on plasmid DNA is
notoriously difficult to perform, we obtained significant
above-background signal following extensive washing and
the use of dynabeads rather than agarose beads (see
Materials and methods). We analysed regions over exons 1
and 3 on both plasmids but observed no evidence of higher
Pol II loading in response to Xrn2 depletion. ChIP using an
antibody (8WG16) to unphosphorylated CTD also revealed
no effect of Xrn2 depletion (our unpublished data). It there-
fore seems likely that the elevated RNA levels observed
following Xrn2 depletion result from reduced degradation
rather than increased Pol II occupancy.
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Figure 2 Roles of hRrp6 and Xrn2 in the degradation of aberrant b-globin transcripts. (A) Western blot showing RNAi depletion of hRrp6
protein. Antibodies were used to detect g-Tubulin (lower panel) or hRrp6 (top panel) in extracts from cells transfected with control or hRrp6-
specific siRNA. (B) Real-time PCR analysis of exon 3-containing b-globin transcripts in chromatin-associated and nucleoplasmic RNA samples
obtained from mock or hRrp6 depleted cells transfected with WT, In1m, pAm, DTIn1m or DTpAm. The diagram shows the position of primers
(arrows). For each transfected gene, values obtained from mock treated cells were set to 1 following normalisation to signal from co-transfected
VA. (C). Western blot showing RNAi depletion of Xrn2 protein. Antibodies were used to detect g-Tubulin (lower panel) or Xrn2 (top panel) in
extracts from cells transfected with control or Xrn2-specific siRNA. Middle panel (marked *) shows a non-specific band detected by the Xrn2
antibody, which acts as an additional loading control. (D) Real-time PCR analysis of exon 3-containing b-globin transcripts in chromatin-
associated and nucleoplasmic samples obtained from mock or Xrn2 depleted cells transfected with WT, In1m, pAm, DTIn1m or DTpAm. The
diagram shows the position of primers (black arrows). For each transfected gene, values obtained from mock treated cells were set to 1
following normalisation to signal from co-transfected VA. (E) Real-time PCR analysis of spliced (exon2-exon3) b-globin transcripts in
chromatin-associated and nucleoplasmic samples obtained from mock or Xrn2 depleted cells transfected with WT, In1m, pAm, DTIn1m or
DTpAm. Diagram shows position of primers (grey arrows). For each transfected gene, values obtained from mock treated cells were set to 1
following normalisation to signal from co-transfected VA. All error bars represent the s.d. from a minimum of three biological replicates.
*indicates P-value of o0.05. Figure source data can be found with the Supplementary data.
Degradation of aberrant pre-mRNA by Xrn2
L Davidson et al
2570 The EMBO Journal VOL 31 | NO 11 | 2012 &2012 European Molecular Biology Organization
Mutant transcripts are bound by Xrn2 in vivo
To get more direct evidence that Xrn2 degrades some mutant
transcripts, we wanted to test whether Xrn2 binds mutant
transcripts in vivo. RNA from cross-linked extracts isolated
from HeLa cells transfected with WT, DTIn1m or DTpAm was
immunoprecipitated with Xrn2-specific antibodies. cDNA was
subsequently synthesised with random hexamers and the
b-globin exon 3 reverse primer. We then analysed exon 3 and
spliced (exon 2-exon 3) b-globin as well as spliced GAPDH
transcripts in all samples by real-time PCR (Figure 3D).
Results were expressed as fold enrichment over background
(no antibody control). All results were shown relative to the
enrichment observed for GAPDH mRNA, which we used as a
negative control. We did not observe any enrichment of exon
3 or spliced RNA in WT samples consistent with it not being
an Xrn2 substrate. However, in DTIn1m and particularly in
DTpAm samples, we observed significant enrichment of exon
3 RNA. Since exon 3 RNA is predominantly unprocessed and
chromatin associated in the mutant samples (Figure 1 and
Supplementary Figure 1), these data indicate that nascent
transcripts that fail to be processed are bound by Xrn2 in vivo.
Interestingly spliced mutant transcripts were not bound sug-
gesting that splicing prevents degradation by Xrn2.
Co-transcriptional degradation of aberrant endogenous
pre-mRNA
Our data provide strong evidence for co-transcriptional
degradation of some aberrant b-globin transcripts by Xrn2.
However, plasmid transcription may not necessarily reflect
chromosomal transcription and most human genes are longer
and more complex than b-globin. We therefore wished to
examine whether co-transcriptional degradation of aberrant
pre-mRNA is a process relevant to endogenous genes. To our
knowledge, nuclear degradation of longer human pre-mRNAs
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produced from their natural chromosomal position has not
been investigated. To do so, we generated a pool of aberrant
pre-mRNA transcripts by treating cells with Spliceostatin A
(SSA) (Kaida et al, 2007). SSA prevents proper function of
SF3b, frequently resulting in a block at the first step of
splicing and often leading to aberrant alternative splicing
(Kaida et al, 2007; Roybal and Jurica, 2010; Corrionero
et al, 2011). We reasoned that SSA treatment should
generate some transcripts that are substrates for Xrn2 if the
protein plays a more widespread role in the turnover of
aberrant pre-mRNA.
A recent microarray analysis looked at the effects of SSA on
pre-mRNA transcripts from human chromosomes 5, 7 and 16
(Kaida et al, 2010). 216 transcripts showed evidence of intron
accumulation, which would be one expected consequence of
splicing inhibition. However, inefficient splicing might
promote transcript degradation and reduce pre-mRNA
levels. We analysed the data from Kaida et al for evidence
of transcripts that are reduced by 2 or more fold following
SSA treatment. Using the same search criteria, we found 366
such transcripts (Figure 4A). Since some of these transcripts
originate from the same gene we also used Ensembl 61 gene
models to analyse the data and find the number of genes
whose transcripts are affected. We found 134 and 234 genes
whose transcripts were, respectively, 2-fold or more up or
down regulated following SSA treatment. Whilst reduced
transcription is a possible explanation for lower levels of
RNA, it is also possible that degradation is responsible in
some cases.
We selected six transcripts that showed a range in fold
change of intron reduction in the microarray analysis follow-
ing SSA treatment: GRAMD3, H2AFY, PDE8B, DAP, EFNA5
and STEAP4. Unlike b-globin, each of these genes is long and
contains multiple introns. To check the effect of SSA on
nascent RNA from these genes, chromatin RNA was isolated
from SSA or MeOH (control) treated cells and reverse tran-
scribed with random hexamers. cDNA was then real-time
PCR amplified to detect intron 1 containing species
(Figure 4B). As additional controls, we analysed TAF7 and
P27 transcripts. TAF7 is intronless and controls for non-
specific SSA effects whereas P27 transcripts are known to
accumulate following SSA treatment (Kaida et al, 2007). After
normalising to TAF7 levels, we observed a B4-fold increase
in P27 pre-mRNA levels, which confirms previous results and
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demonstrates the inhibitory effect of SSA on co-
transcriptional splicing in our system. In contrast, no
accumulation of intronic RNA was evident on any of the
other transcripts analysed. GRAMD3 and H2AFY levels were
similar in control and SSA treated cells whereas DAP, PDE8B,
EFNA5 and STEAP4 levels were reduced. It has been shown
that several transcripts, including P27, accumulate in
nucleoplasmic foci following SSA treatment (Kaida et al,
2007; Brody et al, 2011; Martins et al, 2011). Consistent with
this result we also noted a strong accumulation of P27 pre-
mRNA in the nucleoplasm following SSA treatment; however
the other six transcripts remained predominantly chromatin-
associated (Supplementary Figure 5). These data highlight
distinct effects of SSA on P27 pre-mRNA levels and location
as compared to the other six transcripts analysed.
We next analysed the effect of SSA on co-transcriptional
splicing of the transcripts analysed above. cDNA generated
from chromatin-associated RNA isolated from control and
SSA treated cells was real-time PCR amplified using primers
to detect exon 1-exon 2 splicing (Figure 4C). As expected, a
B3-fold reduction in splicing was observed for P27.
Reductions were also observed for the other six transcripts
with splicing least affected for the GRAMD3 gene. In the
absence of any degradation, a reduction in spliced transcripts
might lead to a corresponding increase in unspliced RNA and
this is observed for P27 (compare Figure 4B and C). Such an
increase in intron levels was not evident for the other six
transcripts, which might be due to their degradation.
A reduction in transcript levels in response to SSA could be
also explained by reduced Pol II occupancy on these genes.
Indeed, mutant b-globin genes, when stably integrated into
chromosomes, sometimes support lower Pol II occupancy (de
Almeida et al, 2010; Mapendano et al, 2010; Martins et al,
2011). We tested for this in our system by analysing Pol II
loading over the same amplicons used for real-time PCR
analysis using ChIP with the 4H8 and S2 antibodies in
control and SSA treated cells (Figure 4D). In most cases, we
observed little difference in Pol II loading. There was a
significant reduction on the PDE8B and DAP genes upon
SSA treatment but this was less marked than the reduction
in RNA observed. Therefore, while reduced transcription
upon SSA treatment occurs in some cases, it may not fully
explain the reduction in RNA levels observed in Figure 4B.
Collectively, these data suggest that degradation may account
for some pre-mRNA loss following SSA treatment.
Xrn2 degrades pre-mRNAs following SSA treatment
We therefore tested whether Xrn2 is involved in the
co-transcriptional degradation of the above six transcripts
following SSA treatment. Mock treated and Xrn2 depleted
cells were treated with MeOH or SSA before isolation of
chromatin-associated RNA. The four RNA samples were
then subjected to real-time PCR analysis to quantitate the
same intron 1 transcripts from each gene (Figure 5A). After
correction to TAF7 levels, there was little difference in the
level of any transcript between MeOH treated mock and Xrn2
depleted cells suggesting that Xrn2 does not degrade these
transcripts under normal conditions. Following SSA treat-
ment, we also observed little effect of Xrn2 depletion on
P27 transcripts. Interestingly P27 transcripts are released into
the nucleoplasm following SSA treatment (Supplementary
Figure 5). As with b-globin In1m transcripts (Figure 2D),
this may facilitate their evasion of Xrn2 activity at the
transcription site (see discussion). Importantly, we observed
an SSA-dependent increase in the level of all other transcripts
upon Xrn2 depletion. Similar differences were also observed
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Figure 5 Xrn2 degrades endogenous pre-mRNAs following treat-
ment with Spliceostatin A. (A) Real-time PCR analysis of intron
transcripts in chromatin-associated RNA isolated from mock treated
or Xrn2 depleted cells treated with MeOH or SSA. Primer pairs
detected the first intron from GRAMD3, H2AFY, PDE8B, EFNA5,
DAP, STEAP4 or P27 transcripts. Graph shows quantitation where
the values obtained from control siRNA transfected cells treated
with MeOH were given a value of 1 after adjustment to TAF7 levels.
Fold increase was calculated from the product ratio in SSA:MeOH in
control and Xrn2 depleted cells and was given a value of 1 in control
cells. (B) ChIP analysis of Pol II loading (4H8 antibody) in mock
treated or Xrn2 depleted cells treated or not with SSA. Graph shows
relative Pol II loading, calculated from the % input of each
immunoprecipitation, which was given a value of 1 in control
siRNA transfected cells treated with MeOH. (C) ChIP of Xrn2
recruitment to chromatin. Quantitation is expressed as percentage
of input DNA immunoprecipitated with anti-Xrn2. The NTS signal
derives from a region on chromosome 10 with no annotated genes.
All error bars represent the s.d. from a minimum of three biological
replicates. * and **indicate P-values of o0.05 and o0.01
respectively.
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when we used alternative primer pairs in different positions
on the same transcripts (Supplementary Figure 6).
Interestingly, hRrp6 depletion had no substantial effect on
any of the transcripts studied implying that it is not necessary
for their degradation and perhaps indicating redundancy
between the exosome and Xrn2 (Supplementary Figure 7).
We also found no evidence that nonsense-mediated decay is
involved in degrading any of the six transcripts affected by
Xrn2 (Supplementary Figure 8). These data implicate Xrn2 in
the degradation of many aberrant pre-mRNAs induced by SSA
treatment.
We next wanted to rule out the possibility of increased Pol
II loading upon Xrn2 depletion combined with SSA account-
ing for increased RNA levels. We therefore performed Pol II
ChIP on control and Xrn2 depleted cells with or without SSA
using the 4H8 antibody and the same intron 1 amplicons
(Figure 5B). With the exception of GRAMD3, where a reduc-
tion in Pol II loading was observed in Xrn2 depleted cells,
there was no change in Pol II ChIP signal as a result of Xrn2
depletion. In addition, no large changes in Pol II loading were
seen in Xrn2 depleted and SSA treated cells when compared
to control cells treated with SSA. Similar results were
achieved with the S2 antibody (Supplementary Figure 9).
Xrn2 is present over relevant regions
Co-transcriptional degradation of pre-mRNA transcripts by
Xrn2 would require the protein to operate in regions of the
gene upstream from the poly(A) site. Consistent with this
possibility, Rat1 and Xrn2 are detectable by ChIP over such
regions (Kaneko et al, 2007; Kim et al, 2010). We therefore
wished to determine whether Xrn2 associated with regions
from which its substrates were generated (Figure 5C). We
performed ChIP analysis using an Xrn2-specific antibody
since the RIP technique employed in Figure 3D was not
sensitive enough to detect the low level transcripts produced
in this experiment. As a positive control we assayed DNA
around the actin poly(A) site, which was previously shown to
be immunoprecipitated with this Xrn2 antibody (Kaneko
et al, 2007). As expected, we were able to immuno-
precipitate this DNA with the Xrn2 antibody. As a negative
control, we analysed a part of chromosome 10 used by others
as a non-transcribed control region (Listerman et al, 2006).
Very little of this DNA was immunoprecipitated. Importantly,
we observed significant immunoprecipitation of the regions
from which Xrn2 sensitive transcripts were produced
following SSA treatment. A similar result was obtained
using an additional Xrn2 antibody (Supplementary
Figure 10). This suggests that Xrn2 is located in close
proximity to regions where aberrant transcripts arise.
Dcp2 depletion stabilises some transcripts following
SSA treatment
Unregulated degradation of RNA from the 50 end is normally
prevented by the cap, which is resistant to Xrn2 degradation
(Stevens and Maupin, 1987). Thus a decapped terminus must
be generated prior to degradation by Xrn2 and this could be
achieved by decapping or endonucleolytic cleavage. Dcp2 is a
major decapping activity conserved in all eukaryotes. The
majority of human Dcp2, when tagged with fluorescent
protein, localizes to the cytoplasm (van Dijk et al, 2002).
However, imaging of endogenous Dcp2 revealed a nuclear
population of the protein that could be relevant to the current
study (Liu et al, 2004). To analyse the location of Dcp2 in
HeLa cells, we performed western blotting on nuclear and
cytoplasmic protein fractions (Figure 6A). The efficiency of
the fractionation procedure was verified by analysis of
Histone H3 and g-Tubulin, which were predominantly nucle-
ar and cytoplasmic respectively. Dcp2, however, was found in
both fractions indicating that there is a nuclear population of
the protein. This remained the case after additional washing
of the nuclei prior to blotting (Supplementary Figure 11). To
test whether Dcp2 might be required to degrade aberrant
transcripts following SSA treatment, we used RNAi to deplete
it from HeLa cells the success of which was confirmed by
western blotting (Figure 6B). Next, total RNA was isolated
from control and Dcp2 depleted cells treated or not with SSA.
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Figure 6 Dcp2 depletion stabilises some SSA sensitive transcripts.
(A) Western blotting of nuclear and cytoplasmic protein fractions
analysing g-Tubulin (top panel), Histone H3 (middle panel) and
Dcp2 (lower panel). (B)Western blot showing RNAi depletion of
Dcp2 protein. Antibodies were used to detect g-Tubulin (lower
panel) or Dcp2 (top panel) in extracts from cells transfected with
control or Dcp2-specific siRNA. (C) Real-time PCR analysis of intron
transcripts in chromatin-associated RNA isolated from mock treated
or Dcp2 depleted cells treated with MeOH or SSA. Primer pairs
detected the first intron from GRAMD3, H2AFY, PDE8B, EFNA5,
DAP or STEAP4 transcripts. Graph shows quantitation, which is
presented as a ratio of each product in SSA vs MeOH treated cells.
The value for each primer pair obtained in mock siRNA treated cells
was set to 1. (D) ChIP of Dcp2 recruitment to chromatin.
Quantitation is expressed as percentage of input DNA immunopre-
cipitated with anti-Dcp2. The NTS signal derives from a region on
chromosome 10 with no annotated genes. All error bars represent
the s.d. from a minimum of three biological replicates.
* and **indicate P-values of o0.05 and o0.01 respectively.
Figure source data can be found with the Supplementary data.
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Following cDNA synthesis with random hexamers, real-time
PCR was performed to detect intron 1 containing transcripts
from the six genes under study (Figure 6C). Three transcripts
(DAP, EFNA5 and GRAMD3) were modestly stabilised in SSA
treated Dcp2 depleted cells when compared to SSA treated
control cells. These data suggest that decapping by Dcp2 can
often generate an entry site for Xrn2 to degrade aberrant
RNA.
Finally, we tested whether Dcp2 was present on transcribed
genes using ChIP (Figure 6D). Consistent with a potential for
decapping of aberrant pre-mRNA, we found Dcp2 to be
present on most of our tested genes (Supplementary
Figure 11). Only a slightly above-background signal was
observed on PDE8B, which may reflect a lack of Dcp2
recruitment to that region or the low transcriptional activity
on that gene. Similar results, though with lower immunopre-
cipitation, were obtained with a separate Dcp2 antibody
(Supplementary Figure 11). Overall these data implicate
Dcp2 in the degradation of some but not all pre-mRNAs
following SSA addition. Since many aberrant transcripts are
not stabilised by Dcp2 depletion, it seems likely that there are
other means of generating decapped substrates for Xrn2 to
degrade (see discussion).
Discussion
One of the major conceptual advances in the transcription
and pre-mRNA maturation fields has been the discovery that
the two processes are functionally coupled (McCracken et al,
1997). As a consequence, it is now known that most splicing
and 30 end processing occur co-transcriptionally in vivo. Since
aberrantly retained introns or uncleaved poly(A) sites would
normally have been processed during transcription it is
logical to propose that such species are degraded
co-transcriptionally. This is an efficient way to remove
potentially harmful transcripts and prevents the synthesis of
unproductive transcripts.
Once a transcript has been identified as defective, the
appropriate degradation machinery must be activated or
recruited to elicit transcript decay. This could be achieved
by recruitment of degradation factors. However, our ChIP
data show that both Xrn2 and Dcp2 are present on genes even
under conditions where splicing is not inhibited. These data
strongly suggest that these factors are always associated with
transcription but only become active in the event of defective
RNA biogenesis. Given that our data are consistent with
degradation being co-transcriptional it would make sense to
have the necessary factors present in this way. In agreement
with our results, genome-wide ChIP analysis of Rat1 revealed
its presence over many gene bodies in addition to the vicinity
of the poly(A) site (Kim et al, 2010). Furthermore, the
exosome complex has also been linked to the transcription
machinery in Drosophila (Andrulis et al, 2002). In both of
these cases, cells were unperturbed in pre-mRNA processing
indicating that exonucleases may ordinarily track with Pol II.
Degradation from the 50 end of RNA requires a decapped
substrate. Indeed, depletion of the decapping enzyme, Dcp2,
stabilised some transcripts following SSA treatment.
Although tagged Dcp2 was previously found predominantly
in the cytoplasm, an endogenous population of nuclear Dcp2
has been observed consistent with our own ChIP and western
blotting analysis (Liu et al, 2004). Moreover, budding yeast
Dcp2 can shuttle between both compartments (Grousl et al,
2009). We find that Dcp2 is frequently not involved in pre-
mRNA degradation upon SSA treatment implying the
existence of other means of transcript decay. An additional
decapping activity (Nudt16) was recently described in human
cells; however this protein was originally reported to be
cytoplasmic (Song et al, 2010) and may therefore be
unlikely to perform this function. Finally, the Rat1 co-factor,
Rai1, possesses decapping activity toward unmethylated caps
(Jiao et al, 2010). Although decapping activity has not been
tested for the human homologue, Dom3Z, we did not observe
any effect of its depletion on degradation of aberrant b-globin
RNA or on transcriptional termination (our unpublished
observations).
Decapping is not the exclusive means of generating
substrates for 50-30 degradation. Indeed, cleavage at the
poly(A) site provides the best defined substrate for these
enzymes (Kim et al, 2004; Gromak et al, 2006). It was
recently shown that blocking the interaction between U1
snRNA and its pre-mRNA target activates processing of
intronic poly(A) signals (Kaida et al, 2010). The authors
also detected a small amount of cleavage product in SSA
treated cells, which presumably would be a potential target
for Xrn2. Cleavage of microRNA-containing introns by
Drosha occurs co-transcriptionally (Morlando et al, 2008) as
does cleavage of b-globin terminator region RNA (Dye and
Proudfoot, 2001). Both of these activities have been shown to
generate Xrn2 substrates (West et al, 2004; Ballarino et al,
2009). RNAse H cleavage of widespread R-loop structures
(RNA:DNA hybrids) could also create entry sites for
exonucleases given their 50 phosphate termini (Mischo
et al, 2011). Finally, the Dis3 subunit of the exosome
possesses endonuclease activity (Lebreton et al, 2008),
though we did not observe a significant effect of its
depletion following SSA treatment (our unpublished
observations). Thus, there may be a range of mechanisms
that provide substrates to Xrn2. Endonucleolytic cleavage of
pre-mRNA would also provide potential exosome substrates.
Our data indicate that transcripts must be efficiently
retained at chromatin sites in order to be degraded by Xrn2.
This is illustrated by comparing bglobin In1m transcripts,
many of which are released, with DTIn1m transcripts that are
not released. Although both produce a partially spliced
b-globin transcript only those deriving from DTIn1m are
degraded by Xrn2. Similarly, P27 pre-mRNAs are efficiently
released into the nucleoplasm following SSA treatment and
are not Xrn2 targets whereas six other pre-mRNAs are not
released but are targeted by Xrn2 upon splicing inhibition.
The determinants of whether aberrant transcripts are
degraded by Xrn2 might be similar to those involved in
releasing RNA from chromatin. These include lack of spli-
cing, failure to assemble spliceosomes and inefficient 30 end
processing and Pol II termination (Dye et al, 2006; West et al,
2008; Martins et al, 2011).
It will be interesting to understand the reasons for the
differential localisation of RNA following SSA treatment. It
has been shown that, while splicing is prevented by SSA
treatment, recruitment of snRNP’s to genes is unaffected
(Schmidt et al, 2011), which may allow the release of
unprocessed RNA. In these instances Pol II might even
terminate transcription, which is something that may also
cause transcript release to be observed. The six transcripts
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studied in detail here are much longer than those previously
studied. Therefore, there is no opportunity to terminate
transcription shortly after splicing failure and so no obvious
means of releasing the RNA. Such circumstances likely
preclude any nucleoplasmic accumulation and then
increase the exposure of these RNAs to co-transcriptional
degradation.
It is now established that most pre-mRNA processing
occurs co-transcriptionally. The current study identifies a
new function for Xrn2 in degrading aberrant pre-mRNA.
It is also the first, to our knowledge, to provide strong
evidence that degradation of many aberrant transcripts initiates
co-transcriptionally.
Materials and methods
Primer sequences and siRNA target sites
See Supplementary Table 1.
Plasmids
The WT, In1m and pAm (previously called HIVb, HIVbIVS1SAmut
and HIVbp(A)mut) have been described (Dye and Proudfoot, 1999).
The Tat plasmid required for trans-activation of the HIV promoter is
also described (Adams et al, 1988) as is the EPO plasmid (West and
Proudfoot, 2009). DTIn1m and DTpAm were constructed by ligation
of a PCR product generated from amplification of In1m and pAm
with the DTf and DTr primer pairs. The VA plasmid contains the
adenovirus VAI gene and was a gift from Nick Proudfoot.
RNA isolation
Nuclear and cytoplasmic RNA fractionation was previously de-
scribed (West and Proudfoot, 2008). Chromatin-associated and
nucleoplasmic RNA was isolated using the protocol described in
(Dye et al, 2006; Wuarin and Schibler, 1994). RNA was treated twice
with Turbo DNase (Ambion). 1mg of RNA was used for reverse
transcription and was isolated from equivalent numbers of cells in
each case. Fractionation and transfection efficiency was analysed by
detection of co-transfection control VA or EPO RNA as well as
endogenous GAPDH mRNA.
Chromatin and RNA immunoprecipitation
The ChIP and RIP protocol was based on a previously published
ChIP protocol by (Glover-Cutter et al, 2008) with modifications
detailed in our Supplementary Material.
Nuclear run on
Nuclear run on was based largely on the protocol in (Ashe et al,
1997) but with specific modifications to incorporate the use of
4-Thio UTP in place of 32P-UTP (see Supplementary Material).
Northern Blotting
5–10mg of total or fractionated RNA was resolved on a glyoxal gel.
Following capilliary transfer, membranes were probed with a
b-globin exon 3 probe made by PCR amplification of WT using
Beta e3f/Betae3r primer pairs using a DECA prime kit (Ambion).
The membrane was washed 2x in 1x SSPE, 0.1% SDS. Bands were
visualised following exposure to a phosphor screen. For our detailed
protocol see Supplementary Material.
Reverse transcription and PCR
1 mg RNA was reverse transcribed using Inprom II (Promega) and
random hexamer primers. Parallel reactions were performed in the
absence of reverse transcriptase. 1/20th of the cDNA mix was used
for real-time PCR using 5–10 pmol of forward and reverse primer
and Sensimix SYBR (Bioline) in a Qiagen Rotorgene machine.
Students t-tests were performed to establish the significance (pre-
sented as P-values) of any important changes observed.
Cell culture
For transient transfections, a 50% confluent 6 cm dish of HeLa cells
was transfected with 0.5mg TAT, 3mg reporter plasmid and 1mg of
VA and EPO plasmids for 4 h using Lipofectamine 2000 (Invitrogen).
RNA was isolated the following day.
For RNAi, 30% confluent 6 cm dishes of cells were transfected
with 18ml 0.2 mM siRNA, using 4.8 ml Lipofectamine RNAiMAX
(Invitrogen), following the manufacturers’ guidelines. RNA or
protein was isolated 48–72 h post-transfection. When plasmid
transfections were performed in conjunction with RNAi, plasmids
were transfected 48 h after the siRNA transfection and RNA ana-
lysed a further 24 h later. For SSA treatment, cells were grown in the
presence of 100 ng/ml SSA for 3 h.
Bioinformatics
We used the data deposited by Kaida et al, 2010 (GEO accession:
GSE24179) and identical search criteria. For transcript analysis we
used the UCSC gene annotations and for genes we used the Ensembl
gene 61 dataset.
Antibodies
4H8 (abcam ab5408), S2 (abcam 5095), hRrp6 (abcam), g-tubulin
(Sigma). Xrn2 ChIP and RIP was performed using Xrn2 antibodies
from Bethyl Labs (A301-103A and A301-102A). Dcp2 ChIP experi-
ments were performed using antibodies from Bethyl labs (A302-
597A) or Sigma (D6319). The antibody used for Xrn2 Western
analysis was a gift from Nick Proudfoot.
Protein fractionation and western blotting
Blots were probed with antibodies to detect Rrp6 (1:1000), Xrn2
(1:1000), g Tubulin (1:2000), Histone H3 (1:2000) and Dcp2
(1:1000). Binding was detected with anti-rabbit (1:5000) or anti-
mouse (1:5000), where appropriate using luminol reagents (Santa
Cruz). Nuclear and cytoplasmic fractions were isolated as for RNA
and nuclear extracts were treated in 100ml RIPA buffer with 1ml
Benzonase (Sigma) for 30 mins at room temperature followed by a
10 min spin at 12000 g.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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